USPTO Has Not Seen ‘Deluge’ Of Inconsistent Statements From Applicants
Executive Summary
Agency did not intend to ‘strong-arm or threaten’ anyone in its duty to disclose notice, patent office legal advisors say. Applicants should assess whether information required by FDA on new method of manufacturing or different formulation impacts patentability.
You may also be interested in...
FDA-USPTO Collaboration: Stakeholders Want More Clarity On Orange Book Patent Listings
Officials from the two agencies note the real-world benefit of cross-training in helping patent examiners find prior art based on product labeling. A USPTO administrative patent judge also nixes a suggestion that the agency hold proceedings to determine if patents were properly listed in the Orange Book.
Pharma Industry Wants USPTO To Hit Brakes On Changes To Patent Continuation Practice
AbbVie, Amgen, Genentech, Bristol-Myers Squibb and others call on the patent office to retain the current system for continuation applications in comments on the USPTO and FDA’s proposed initiatives.
Unjustifiable Delays In Generic Competition? Biopharma Contends There Is No Problem
As Congress prepares to again debate patent reforms, brand industry says allegations of ‘patent thickets’ and extended market exclusivity are based on inaccurate or misleading data. They assert there is no need for PTO and FDA to institute systemic policy changes.